Studies in hypothyroid rats show that, when infused with a combination of thyroxine (T4) plus triiodothyronine (T3) to normalize thyrotropin (TSH), euthyroidism in all organs is only ensured when T 4 and T 3 are administered in a ratio as normally secreted by the rat thyroid. As substitution with T 4 -only results in an abnormal serum T 4 /T 3 ratio, it is also possible that in humans, euthyroidism does not exist at the tissue level in many organs, considering that iodothyronine metabolism in the human and the rat share many similar mechanisms. Recent reports in which cognitive function and well-being are compared in patients with primary hypothyroidism substituted with T 4 -only versus substitution with T 4 plus T 3 result in controversial findings in that either positive or no effects were found. In all these studies T 3 was used in the plain form that results in nonphysiologic serum T 3 peaks. In these studies it is suggested that substitution with T 3 should preferably be performed with a preparation that slowly releases T 3 to avoid these peaks. In the study reported here we show that treatment of hypothyroid subjects with a combination of T 4 plus slow-release T 3 leads to a considerable improvement of serum T 4 and T 3 values, the T 4 /T 3 ratio and serum TSH as compared to treatment with T 4 -only. Serum T 3 administration with slow-release T 3 did not show serum peaks, in contrast to plain T 3 .
Introduction

T
HE INTRODUCTION OF synthetic levothyroxine for thyroid hormone replacement therapy several decades ago signified an important improvement over the use of desiccated thyroid powder that contained thyroxine (T 4 ) plus triiodothyronine (T 3 ) in a varying ratio because it was only standardized in its iodine content. Recent interest to return to a now stable T 4 /T 3 combination that mimics normal serum thyroid function parameters as closely as possible, stimulated studies comparing the effects of substitution with T 4 alone versus a fixed T 4 /T 3 combination. These studies showed different results. Thus positive effects on health and well-being (1-3) as well as ineffectiveness (4) (5) (6) or even negative effects in some parameters (4) were noted. In two editorials (7, 8 ) the pro and cons of these studies are discussed and suggestions were made for future studies to solve the discrepant findings. One of these recommendations is the use of T 3 in sustained release manner. "Plain" T 3 is rapidly absorbed into the bloodstream and also because of its short half-life of approximately 1 day, results in unwanted nonphysiologic serum peaks (9) . Already in 1993 in a review on the use and misuse of thyroid hormone it was stated: "Perhaps the truly ideal substitution therapy for hypothyroidism might be a combination of LT 4 , and LT 3 in a carefully determined ratio and in a form in which the LT 3 is slowly absorbed in a time-released form" (10) .
In the present study we therefore addressed the following questions: (1) does a once-daily treatment with T 4 and slowrelease (SR) T 3 lead to a constant serum T 3 level without peaks and (2) does the use of a combination treatment of T 4 plus SR-T 3 in a specific ratio results in normalization of serum thyrotropin (TSH) T 4 , and T 3 concentrations? To these ends, patients treated with levothyroxine (LT 4 ) only for primary hypothyroidism were switched in an open, random, crossover manner to two regimens of substitution with a combination preparation of T 4 1 plain (PL) T 3 and T 4 1 SR-T 3 .
Materials and Methods
Patients
Inclusion criteria were: patients of either gender with primary hypothyroidism, using between 100 and 175 mg LT4 (Thyrax ® , Organon BV, The Netherlands), preferably 150 mg, for at least 3 months. They should otherwise be healthy. Each patient gave written informed consent. Exclusion criteria were: the use of any other medication and age of 80 years and above.
Eighteen patients were selected, fulfilling the inclusion criteria. One patient was excluded because of vaso-vagal col-lapse after (the first) vena-puncture, 1 patient because of a car accident and subsequently hospitalization during the study, and 1 patient because of improper use of study medication. The 15 included patients consisted of 12 females and 3 males, with a mean age of 50 years (range 26-79 years). Fourteen patients were using 150 mg LT 4 daily and 1 patient used 125 mg LT 4 daily. The causes of primary hypothyroidism were: 131 I treatment for Graves' disease, Hashimoto's thyroiditis, congenital hypothyroidism, neck irradiation for Hodgkin's disease and subtotal thyroidectomy for nodular goiter.
Study design
Three 6-week periods were discerned. In the first 6 weeks the patients were kept on their LT 4 dose that they were using before. Then patients were switched either to a combination therapy containing 125 mg T 4 (Thyrax ® , Organon BV) and 6 mg PL-T 3 (inhouse normal release preparation using Cytomel ® as T 3 compound) daily, or to a combination therapy containing 125 mg T 4 and 6 mg SR-T 3 (in-house slow-release preparation and using Cytomel ® as T 3 compound) The combination treatments were performed in a randomized crossover design. During the sixth week of each study period, one blood sample was taken on day 3, and 5 serial blood samples were taken on day 5 at 8:00 AM (i.e., 15 minutes before ingestion of the medication), and at 09:45, 11:15, 2:15, and 5:15. Mean serum T 4 and T 3 and median serum TSH concentrations were calculated from the fifth day samples. It appeared that the T 4 , T 3 , and TSH values on the third day did not differ significantly from those on the fifth day at time point 215 minutes, indicating that equilibrium was reached. Patients were at rest at least half an hour before each blood sample was taken.
Laboratory methods
Serum T 4 and T 3 were measured by in-house radioimmunoassay (RIA); TSH by Amerlite 30 Amersham, United Kingdom. Within-assay coefficients of variation were 2%-8% for T 4 , 2%-6% for T 3 , and 2-5% for TSH.
Calculations
Statistical analysis was either done with the paired two tailed test for T 4 , T 3 , T 4 /T 3 ratios, the maximal concentration of T 3 (C m ax ), the time of the maximal concentration (t m ax ), and the area under the T 3 curve from 0 to 24 hours (AUC 0-24 ) or with the Mann-Whitney two-tailed test for TSH. The AUC 0-24 , was calculated by means of the linear trapezoidal rule, taking the predose value as the 24-hour point. Figure  1C shows the mean serum T 4 /T 3 ratio that was significantly higher on T 4 -only than on T 4 plus PL-T 3 (p , 0.0001), T 4 plus SR-T 3 (p , 0.0001) and in controls (p , 0.0001), while the T 4 /T 3 ratio on T 4 plus PL-T 3 was significantly lower than on T 4 plus SR-T 3 (p 5 0.026). In Figure 1D , the median serum TSH on T 4 -only treatment was not significantly lower than on T 4 plus PL-T 3 (p 5 0.11), but significantly lower than on T 4 plus SR-T 3 (p 5 0.033) and than in controls (p , 0.0001), while no significant difference was present between the two combination preparations (p 5 0.14). TSH concentrations during treatment with T 4 plus PL-T 3 and T 4 plus SRT 3 were significantly lower than in controls (both p , 0.0001).
In Figure 2 , the mean serum T 4 ( Fig. 2A) and T 3 ( Fig. 2B ) and median TSH (Fig. 2C) are depicted for all subjects for each of the three regimens during the 9-hour sampling on the fifth day of the sixth study week. It can be seen that serum T 4 shows a limited but steady rise during sampling in all three treatments without any significant difference between them. During T 4 plus PL-T 3 , serum T 3 shows a considerable peak between 0 and 6 hours, whereas during T 4 plus SR-T 3 no peak is present but a slight rise similar to T 4 . No substantial change in T 3 concentrations is seen during T 4 -only treatment. The pharmacokinetics of T 3 during both combination treatments are depicted in the Table 1 . The data show that the AUC 0-24 of T 3 during both treatments are virtually
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FIG. 2. Mean of serum thyroxine (T 4 ;
A), triiodothyronine (T 3 ; B) and median thyrotropin (TSH; C) of all subjects, during 9-hours sampling at the fifth day of the sixth treatment week for each of the three regimens. T4, thyroxine; PL-T3, plain triiodothyronine; SR-T3, slow-release triiodothyronine; Cmax, maximal concentration; AUC 0-24 , area under the curve from 0-24 hours; T max , time point of C max .
the same, while C max and T max of T 3 during the SR-T 3 regimen are significantly lower and later, respectively, than during PL-T 3 .
Discussion
Substitution of thyroid function with LT 4 in patients with primary hypothyroidism, when titrated to normalize serum T 4 , results in a mean serum T 3 level that is lower than normal. However, when T 4 is administered in amounts to normalize serum T 3 , T 4 parameters will rise to supranormal concentrations (11, 12) . The reason for this is that the thyroidal contribution to serum T 3 , which is approximately 20% of total serum T 3 (13) , is lacking in patients with absent thyroid function. Thus, in this situation all plasma T 3 is derived from T 4 . Hence, in T 4 substitution, more T 4 has to reach the plasma compartment than under normal conditions to ensure normal plasma T 3 . Consequently, whatever dose of T 4 is substituted, the serum T 4 /T 3 ratio will always be abnormal, that is, elevated. It has been established in rats that the extent to which nuclear receptor-bound T 3 is derived from plasma T 3 and from local T 3 production from T 4 varies among tissues. Thus, for instance, nuclear T 3 in cerebral cortex is derived for approximately 80% from local conversion of T 4 , in pituitary for approximately 50%, in skeletal muscle for approximately 40%, and in liver for only approximately 5% (14, 15) . When rats are infused with T 4 in combination with T 3 in the same ratio in which they are normally secreted, the euthyroid state in all of the many tissues studied is ensured. Any variation of this ratio leads to tissue hypothyroidism or hyperthyroidism in various organs (16) .
Although the exact contribution of the different sources of nuclear T 3 in human tissues is unknown, there are many similarities regarding thyroid hormone production and metabolism between rat and humans (17) . Therefore, it would not be surprising if a similar situation with regard to the negative tissue effects of an abnormal plasma T 4 /T 3 ratio would exist in humans as well. For instance, when T 4 is administered in a dose such that serum T 3 is normal, serum T 4 parameters will be increased and serum TSH will be suppressed (18) because thyrotropic nuclear T 3 occupancy is importantly dependent on plasma T 4 .
The ratio that we used in this study was based on data of thyroid hormone secretion and intestinal absorption in humans (19, 20) . The pharmacokinetics of T 3 show that the slowrelease preparation is indeed slowly releasing T 3 in vivo as the T max occurs significantly later and the C max is significantly lower than in the case of plain T 3 . The total amount absorbed (see AUC) is the same for both preparations. Despite the fact that thyroid function parameters and the T 4 /T 3 ratios improved substantially in the combination regimens, they were still not normal (Fig. 1) . The combination treatment with slowrelease T 3 did not result in a serum T 3 peak but only in a slow rise of T 3 after intake, comparable to that of T 4 ( Fig. 2a and  2b) . The relative variation of TSH in the three regimens is not different and one could wonder why during T 4 plus PL-T 3 serum TSH fluctuation is not at variance with that in the other two treatments. However, it should be realized that TSH secretion is importantly dependent on serum T 4 (14, 15) , that may dilute any effect of serum T 3 variations.
From this study it is apparent that using a slow-release T 3 preparation, nonphysiologic T 3 peaks are avoided. We suggest that in future studies on the effects of T 4 plus T 3 , only sustained release T 3 preparations are being used.
